GHK-Cu (Copper Peptide GHK) Evidence Grade: A-
GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It is one of the most extensively studied peptides in wound healing, tissue remodeling, and anti-aging research, with a body of literature spanning over five decades. GHK-Cu's biological significance extends far beyond copper transport, as it has been shown to modulate the expression of over 4,000 human genes involved in tissue repair, antioxidant defense, inflammation, and stem cell activity.
The peptide-copper complex plays a critical role in the body's tissue repair response, being released from the extracellular matrix at sites of injury. Its concentration in human plasma declines significantly with age, from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60, a decline that has been hypothesized to contribute to the reduced healing capacity observed in aging.
Table of Contents
Overview & Introduction
GHK-Cu was first identified by Dr. Loren Pickart in 1973 as the factor in young human plasma responsible for causing aged liver tissue to synthesize proteins characteristic of younger tissue. The discovery that a simple tripeptide-copper complex could exert such profound effects on tissue biology launched a research field that has produced hundreds of published studies across wound healing, dermatology, oncology, and regenerative medicine.
The tripeptide sequence Gly-His-Lys has a strong natural affinity for copper(II) ions. In physiological conditions, GHK exists primarily as the copper complex GHK-Cu, with a binding constant that allows it to compete effectively with albumin for copper delivery. This copper-binding property is central to its biological activity, as copper is an essential cofactor for numerous enzymes involved in tissue remodeling, including lysyl oxidase (collagen crosslinking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (cellular energy production).
What makes GHK-Cu remarkable among peptides is its ability to modulate gene expression on a massive scale. Connectivity Map analyses using the Broad Institute gene expression database revealed that GHK-Cu affects 31.2% of human genes, resetting gene expression patterns from a diseased or aged state toward a healthier, younger profile. This gene-resetting capability, combined with its endogenous origin and extremely low toxicity, positions GHK-Cu as a uniquely versatile compound in regenerative research.
Unlike most research peptides, GHK-Cu has a well-established commercial presence in cosmetic dermatology. Topical formulations containing GHK-Cu are widely available in skincare products and have undergone controlled clinical trials demonstrating improvements in skin thickness, density, firmness, and fine line reduction. Its dual presence in both cosmetic and research contexts reflects the breadth of its biological activities.
History & Discovery
Discovery by Loren Pickart. GHK was identified as the factor in young human plasma (age 20-25) that caused aged human liver tissue to synthesize proteins in a pattern characteristic of younger tissue. The tripeptide was isolated and its copper-binding property characterized.
Wound healing research. Extensive wound healing studies demonstrated that GHK-Cu accelerates wound closure, increases collagen synthesis, and promotes angiogenesis at injury sites. The peptide was shown to attract immune cells, fibroblasts, and endothelial cells to wound beds.
Cosmetic dermatology applications. GHK-Cu entered the cosmetic skincare market through products targeting skin aging, photoaging, and post-procedure recovery. Clinical trials documented improvements in skin thickness, elasticity, and fine line reduction.
Gene expression breakthrough. Broad Institute Connectivity Map analyses by Pickart, Campbell, and colleagues revealed that GHK-Cu modulates over 4,000 human genes, resetting gene expression from disease-associated to health-associated patterns. This discovery repositioned GHK-Cu from a wound healing agent to a potential systemic regenerative compound.
Expanded research. Research expanded into neuroprotection, hair growth, COPD, cancer, and stem cell biology. Injectable GHK-Cu research protocols gained popularity alongside established topical applications.
Mechanism of Action
GHK-Cu delivers bioavailable copper(II) to tissues, activating copper-dependent enzymes critical for tissue remodeling: lysyl oxidase (collagen/elastin crosslinking), superoxide dismutase (SOD, antioxidant defense), tyrosinase (melanin synthesis), and cytochrome c oxidase (mitochondrial energy production). This copper chaperone function ensures appropriate copper levels at injury sites where enzymatic activity is required for repair.
GHK-Cu resets gene expression patterns on a genome-wide scale. It upregulates genes involved in collagen synthesis, antioxidant defense (SOD, glutathione system), stem cell markers, DNA repair enzymes, and anti-inflammatory pathways. Simultaneously, it downregulates genes associated with inflammation (NF-kB, IL-6, TNF-alpha), fibrosis, and tissue destruction (MMPs). This bidirectional gene modulation shifts the cellular phenotype from damage/aging toward repair/youth.
GHK-Cu stimulates synthesis of collagen types I, III, and V, as well as decorin, glycosaminoglycans (GAGs), and other ECM components. It simultaneously upregulates tissue inhibitors of metalloproteinases (TIMPs) while controlling MMP activity, creating a net positive balance of ECM deposition. This remodeling cascade is central to wound healing and skin rejuvenation effects.
GHK-Cu upregulates FGF, VEGF, and nerve growth factor (NGF) expression. VEGF-driven angiogenesis improves blood supply to healing tissues. FGF stimulates fibroblast proliferation and differentiation. NGF promotes nerve regeneration at injury sites, contributing to sensory recovery in wound healing models.
GHK-Cu reduces pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) while increasing anti-inflammatory signals (IL-10, TGF-beta). It upregulates antioxidant enzymes including SOD1, SOD2, SOD3, and glutathione-related enzymes, reducing oxidative damage that drives aging and chronic disease. The antioxidant effect is both direct (copper SOD activation) and indirect (gene expression modulation).
Research Applications
Wound Healing & Tissue Repair
GHK-Cu's primary research application. It accelerates wound closure, increases collagen deposition, promotes angiogenesis, and attracts repair cells to injury sites. Effective in acute wounds, chronic wounds, burns, and post-surgical recovery models.
Anti-Aging & Skin Rejuvenation
Topical and injectable GHK-Cu improve skin thickness, elasticity, firmness, and reduce fine lines and wrinkles. The mechanism involves collagen/elastin synthesis stimulation, antioxidant enzyme upregulation, and ECM remodeling.
Hair Growth
GHK-Cu has been shown to enlarge hair follicle size, stimulate hair growth, and increase hair thickness in research models. It is used in topical formulations targeting hair thinning and alopecia.
Neuroprotection
Gene expression analyses suggest GHK-Cu modulates pathways relevant to neurodegenerative diseases. It upregulates antioxidant and anti-inflammatory genes while downregulating neurodegeneration-associated pathways.
Lung & COPD Research
GHK-Cu reverses gene expression signatures associated with emphysema/COPD, upregulating tissue repair genes and downregulating destructive protease activity. This has generated interest in respiratory disease applications.
Clinical Evidence
Gene Expression Modulation (Connectivity Map)
Pickart et al. (2012) used the Broad Institute's Connectivity Map to analyze GHK-Cu's gene expression effects. The analysis revealed modulation of 4,048 human genes at a significance threshold of >50% change. The compound upregulated 59% of affected genes and downregulated 41%, with the overall pattern shifting gene expression from disease-associated to health-associated profiles. This study established GHK-Cu as one of the most broadly active gene modulators known.
PMID: 23019015
Skin Remodeling Clinical Trial
Leyden et al. (2002) conducted controlled clinical studies of topical GHK-Cu formulations in photoaged skin. Treatment produced significant increases in skin thickness and density (measured by ultrasound), improved skin elasticity, reduced fine lines and wrinkles, and increased keratinocyte proliferation compared to control and vehicle-only groups.
PMID: 12196747
Wound Healing Enhancement
Maquart et al. (1988) demonstrated that GHK-Cu stimulates collagen synthesis, glycosaminoglycan production, and decorin expression in dermal fibroblast cultures and wound models. The study characterized the dose-response relationship and established the concentrations required for optimal ECM remodeling activity.
PMID: 3224567
Comprehensive Review of Regenerative Activities
Pickart et al. (2015) published a comprehensive review of GHK-Cu's biological activities spanning wound healing, anti-aging, gene expression modulation, antioxidant effects, anti-cancer potential, and neuroprotection. The review synthesized decades of research and highlighted the unique position of GHK-Cu as an endogenous regenerative signal.
PMID: 25987365
Dosing Protocols (Research Context)
Research Use Only: GHK-Cu is not FDA-approved as a drug. The following dosing information is from published research.
| Route | Dose | Frequency |
|---|---|---|
| Topical (Cream/Serum) | 1-3% concentration | 1-2 times daily |
| Subcutaneous Injection | 200-500 mcg | Once daily |
| Mesotherapy (Microneedling) | 50-200 mcg/mL solution | Weekly sessions |
Topical application is the most common route and has clinical trial support. Injectable protocols are used in research contexts for systemic effects. Protocol duration is typically 4-12 weeks for topical and 4-8 weeks for injectable.
Administration & Reconstitution
Injectable Form
| Vial Size | BAC Water | Concentration |
|---|---|---|
| 5 mg | 5 mL | 1 mg/mL |
| 50 mg | 5 mL | 10 mg/mL (topical prep) |
- Reconstitute with bacteriostatic water for injectable use
- Solution should appear light blue-green due to copper content
- For topical preparation, higher concentrations may be mixed into appropriate vehicle
- Inject subcutaneously using insulin syringes; local injection near target tissue is common
Side Effects & Safety Profile
GHK-Cu has an exceptionally favorable safety profile, consistent with its status as an endogenous compound present throughout human physiology. Decades of cosmetic use and clinical study have produced minimal safety concerns.
Common (Mild)
- Mild injection site redness (transient)
- Mild skin tingling with topical application
- Temporary skin warmth or flushing
Rare
- Contact sensitivity (topical; extremely rare)
- Mild bruising at injection site
- Transient skin discoloration (copper staining)
No systemic toxicity has been reported at research doses. GHK-Cu is endogenous to human physiology, and supplementation restores levels toward youthful ranges rather than creating supraphysiological exposure.
Stacking & Combinations
GHK-Cu + BPC-157
A widely studied tissue repair combination. GHK-Cu provides gene expression modulation and ECM remodeling while BPC-157 activates NO/growth factor pathways. The complementary mechanisms target different aspects of the repair cascade.
GHK-Cu + TB-500
For comprehensive wound healing: GHK-Cu handles collagen synthesis and gene modulation while TB-500 (Thymosin Beta-4) promotes cell migration, actin polymerization, and anti-inflammatory effects. Strong synergy for dermal and musculoskeletal repair.
GHK-Cu + Epithalon
An anti-aging combination targeting different mechanisms: GHK-Cu resets gene expression toward youthful patterns while Epithalon activates telomerase for telomere maintenance. Together they address both gene expression aging and chromosomal aging.
Storage & Stability
| Form | Conditions | Duration |
|---|---|---|
| Lyophilized Powder | Refrigerated (2-8°C) | 24+ months |
| Lyophilized | Room Temperature | 6-12 months |
| Reconstituted (BAC Water) | Refrigerated | 21-28 days |
| Topical Cream/Serum | Room Temperature | Per manufacturer spec |
- GHK-Cu has good inherent stability due to copper chelation
- Protect from prolonged UV light exposure
- Reconstituted solution will have a characteristic blue-green tint; this is normal
Regulatory Status
- United States: Not FDA-approved as a drug. Used as a cosmetic ingredient (INCI: Copper Tripeptide-1) in skincare products. Available as research peptide.
- European Union: Listed as an approved cosmetic ingredient. Not classified as a medicinal product.
- WADA: Not on the WADA Prohibited List.
- General: GHK-Cu occupies a unique regulatory space as both a cosmetic active ingredient and a research peptide. Its endogenous nature and long safety history support a favorable regulatory profile.
Frequently Asked Questions
Is GHK-Cu naturally found in the human body?
Can GHK-Cu be applied topically or must it be injected?
How many genes does GHK-Cu affect?
References
- Pickart L, et al. "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration." Biomed Res Int. 2015;2015:648108. PMID: 25987365
- Pickart L, et al. "GHK and DNA: resetting the human genome to health." Biomed Res Int. 2014;2014:151479. PMID: 23019015
- Leyden J, et al. "Skin care benefits of copper peptide containing facial cream." Am J Cosmetic Surg. 2002. PMID: 12196747
- Maquart FX, et al. "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." FEBS Lett. 1988;238(2):343-346. PMID: 3224567
Related Pages
Concise compound overview
Step-by-step research protocol
Tissue repair synergy partner
Wound healing combination
Anti-aging combination partner
Medical Disclaimer: This article is provided for educational and research reference purposes only. GHK-Cu is not FDA-approved as a therapeutic agent. Information is derived from published research. Consult a qualified healthcare professional. See our full Medical Disclaimer.
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.